Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-09-16T00:15:56.644Z.
Consensus retrieved: 2026-09-13T23:29:52.709Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-16T00:15:56.644Z.
Quote observation: 2026-09-15T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19e5010cd34a848df86eef5fa49b647d89bc6ef8f6902ab99c9afc77e7f09360
FORWARD PE RATIO
N/A
Novo Nordisk A/S
Market Cap
$188.86B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Novo Nordisk A/S (NVO) | $188.86B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $181.64B | N/A |
| Abbott Laboratories (ABT)vs › | $176.59B | 18.50 |
| Amgen Inc. (AMGN)vs › | $202.74B | 16.28 |
| Pfizer Inc. (PFE)vs › | $157.02B | 9.26 |
| Danaher Corporation (DHR)vs › | $147.13B | 24.61 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $238.35B | 25.54 |
| Intuitive Surgical, Inc. (ISRG)vs › | $133.24B | 34.92 |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $130.62B | 27.45 |
| Bristol-Myers Squibb Company (BMY)vs › | $130.18B | 9.20 |
Trailing P/E
10.5
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
Consensus estimates for this stock are reported in DKK, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
